UNAIDS. UNAIDS Data. 2021. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021. Contract No.: Licence: CC BY-NC-SA 3.0 IGO.

Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. eClinicalMedicine. 2022;48.

Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from Efavirenz-Based to integrase strand transfer Inhibitor-Based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–31.

Article  PubMed  PubMed Central  Google Scholar 

Surial B, Mugglin C, Calmy A, Cavassini M, Gunthard HF, Stockle M et al. Weight and metabolic changes after switching from Tenofovir disoproxil fumarate to Tenofovir Alafenamide in people living with HIV: A cohort study. Ann Intern Med. 2021.

Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2019.

Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. HIV-Infected women gain more weight than HIV-Infected men following the initiation of antiretroviral therapy. J Women’s Health. 2018;27(9):1162–9.

Article  Google Scholar 

Bedimo R, Adams-Huet B, Taylor BS, Lake J, Luque A. 538. Integrase Inhibitor-Based HAART is associated with greater BMI gains in blacks, hispanics, and women. Open Forum Infect Dis. 2018;5(suppl1):S199–S.

Article  PubMed Central  Google Scholar 

Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR et al. Risk factors for weight gain following switch to integrase Inhibitor-Based antiretroviral therapy. Clin Infect Dis. 2020.

Hamzah L, Post FA. Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir. Aids. 2021;35(2):349–51.

Article  CAS  PubMed  Google Scholar 

Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5).

Abelman RA, Ma Y, Mehta CC, Yang Q, Xia F, Brock JB, et al. Switch to integrase strand transfer inhibitors during the menopausal transition is associated with accelerated body composition change in women with human immunodeficiency virus. Clinical Infectious Diseases; 2024.

Blevins SR, Hester EK, Chastain DB, Cluck DB, Doravirine. A return of the NNRTI class?? Ann Pharmacother. 2020;54(1):64–74.

Article  CAS  PubMed  Google Scholar 

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Department of Health and Human Services2021 [updated June 3, 2021. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf

Molina J-M, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted Darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020;7(1):e16–26.

Article  PubMed  Google Scholar 

Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81(4):463–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orkin C, Squires KE, Molina J-M, Sax PE, Sussmann O, Lin G, et al. Doravirine/Lamivudine/Tenofovir disoproxil fumarate (TDF) versus efavirenz/emtricitabine/tdf in Treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, Double-blind, phase 3 DRIVE-AHEAD noninferiority trial. Clin Infect Dis. 2020;73(1):33–42.

Article  PubMed Central  Google Scholar 

Rock AE, Lerner J, Badowski ME. Doravirine and its potential in the treatment of HIV: an Evidence-Based review of the emerging data. HIV AIDS (Auckl). 2020;12:201–10.

CAS  PubMed  Google Scholar 

Centers for Disease Control and Prevention. HIV, Surveillance Report. vol. 34: Diagnoses of HIV Infection in the United States and Dependent Areas, 2021 2023 [updated 23 May 2023. Available from: https://stacks.cdc.gov/view/cdc/149071

Fryar C, Gu Q, Ogden C. Anthropometric reference data for children and adults: united states, 2007–2010. Natl Cent Health Stat Vital Health Stat. 2012;11:252.

Google Scholar 

Kumar P, Johnson M, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Brief report: switching to DOR/3TC/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial. JAIDS J Acquir Immune Defic Syndr. 2021;87(2):801–5.

Article  CAS  PubMed  Google Scholar 

Fox M, Mills AM, Ramgopal M, Bettacchi CJ, Osiyemi O, Hinestrosa F, et al. editors. Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1. Conference on Retroviruses and Opportunitic Infections; 2025; San Francisco, CA, USA.

Fox M, Mngqibisa R, Velez JD, Kumar P, Braun DL, Carr A, et al. editors. Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1. Conference on Retroviruses and Opportunistic Infections; 2025; San Francisco, CA, USA.

Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G et al. Antiretrovirals and weight change: weighing the evidence. Clin Infect Dis. 2024:ciae191.

Kousari AE, Wilson MP, Hawkins KL, Bandali MM, Henao-Martínez AF, Gardner EM, et al. Weight change with antiretroviral switch from integrase inhibitor or Tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV. HIV Res Clin Pract. 2024;25(1):2339576.

Article  PubMed  PubMed Central  Google Scholar 

Mazzitelli M, Antoni MD, Castelli F, Ripamonti D, Zuglian G, Lapadula G, et al. Real-life use of doravirine in treatment-experienced people living with HIV: A multicenter Italian study. Med (Baltim). 2022;101(30):e29855.

Article  CAS  Google Scholar 

Calza L, Colangeli V, Pensalfine G, Appolloni L, Vitale S, Bon I, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. Int J STD AIDS. 2023;34(14):1018–23.

Article  CAS  PubMed  Google Scholar 

Woods J, Sokhela S, Akpomiemie G, Bosch B, Möller K, Bhaskar E, et al. DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025;26(1):81–96.

Article  CAS  PubMed  Google Scholar 

Woods J, Sokhela S, Akpomiemie G, Bosch B, Möller K, Bhaskar E et al. DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir‐or efavirenz‐to doravirine‐based first‐line antiretroviral therapy. HIV Med. 2024.

Dupont E, Yombi JC. Antiretroviral therapy and weight gain in antiretroviral treatment-experienced HIV patients: A review. AIDS Rev. 2023;25(1):54–64.

Article  PubMed  Google Scholar 

Abelman RA, Nguyen TTJ, Ma Y, Bacchetti P, Messerlian G, French AL et al. Body composition changes over the menopausal transition in women with and without human immunodeficiency virus. Clin Infect Dis. 2023:ciad165.

Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. Cohort study. J Int AIDS Soc. 2021;24(4):e25702.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lake JE, Trevillyan J. Impact of integrase inhibitors and Tenofovir Alafenamide on weight gain in people with HIV. Curr Opin HIV AIDS. 2021;16(3):148–51.

Article  CAS  PubMed  Google Scholar 

Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the united States and Canada. J Int AIDS Soc. 2020;23(4):e25484.

Article  PubMed  PubMed Central  Google Scholar 

Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, et al. Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: A Propensity-Weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus. Open Forum Infect Dis. 2021;8(12):ofab537.

Article  PubMed  PubMed Central  Google Scholar 

Orkin C, Elion R, Thompson M, Rockstroh JK, Alvarez Bognar F, Xu ZJ, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021;35(1):91–9.

Article  CAS  PubMed  Google Scholar 

Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, Günthard HF, De Wit S, et al. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV. 2021;8(11):e711–22.

Article  CAS  PubMed  Google Scholar 

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255–68.

Article  CAS  PubMed  Google Scholar 

Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–9.

Article  PubMed  PubMed Central  Google Scholar 

Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia BM, et al. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO registry. Int J Antimicrob Agents. 2023;61(3):106737.

Article  CAS  PubMed  Google Scholar 

Spivack S, Pagkalinawan S, Samuel R, Koren DE. HIV: how to manage heavily treatment-experienced patients. Drugs Context. 2022;11:2021–9.

Article  PubMed  PubMed Central  Google Scholar